Survival: ITT population, unblinded assessment
| . | Treated with ABX-CBL . | Treated with ATG . |
|---|---|---|
| No. patients | 48 | 47 |
| Survival time | ||
| Median d (min d, max d)* | 64.5 (6, 682) | 119 (6, 768) |
| Censored, no. | 13 | 8 |
| Cause of death, no. (%) | ||
| GVHD related | 19 (40) | 9 (19) |
| Primary disease related | 3 (6) | 2 (4) |
| Other | 13 (27) | 28 (60) |
| Probability of 180-day survival (K-M) | 0.354 | 0.447 |
| 95% confidence interval | (0.219, 0.489) | (0.305, 0.589) |
| 95% confidence interval for difference | (−0.289, 0.104) | |
| . | Treated with ABX-CBL . | Treated with ATG . |
|---|---|---|
| No. patients | 48 | 47 |
| Survival time | ||
| Median d (min d, max d)* | 64.5 (6, 682) | 119 (6, 768) |
| Censored, no. | 13 | 8 |
| Cause of death, no. (%) | ||
| GVHD related | 19 (40) | 9 (19) |
| Primary disease related | 3 (6) | 2 (4) |
| Other | 13 (27) | 28 (60) |
| Probability of 180-day survival (K-M) | 0.354 | 0.447 |
| 95% confidence interval | (0.219, 0.489) | (0.305, 0.589) |
| 95% confidence interval for difference | (−0.289, 0.104) | |
Min indicates minimum uncensored time; max, maximum uncensored time.